» Articles » PMID: 34489337

Associations of Systemic Health and Medication Use with the Enlargement Rate of Geographic Atrophy in Age-related Macular Degeneration

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 2021 Sep 7
PMID 34489337
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The associations of geographic atrophy (GA) progression with systemic health status and medication use are unclear.

Methods: We manually delineated GA in 318 eyes in the Age-Related Eye Disease Study. We calculated GA perimeter-adjusted growth rate as the ratio between GA area growth rate and mean GA perimeter between the first and last visit for each eye (mean follow-up=5.3 years). Patients' history of systemic health and medications was collected through questionnaires administered at study enrolment. We evaluated the associations between GA perimeter-adjusted growth rate and 27 systemic health factors using univariable and multivariable linear mixed-effects regression models.

Results: In the univariable model, GA perimeter-adjusted growth rate was associated with GA in the fellow eye at any visit (p=0.002), hypertension history (p=0.03), cholesterol-lowering medication use (p<0.001), beta-blocker use (p=0.02), diuretic use (p<0.001) and thyroid hormone use (p=0.03). Among the six factors, GA in the fellow eye at any visit (p=0.008), cholesterol-lowering medication use (p=0.002), and diuretic use (p<0.001) were independently associated with higher GA perimeter-adjusted growth rate in the multivariable model. GA perimeter-adjusted growth rate was 51.1% higher in patients with versus without cholesterol-lowering medication use history and was 37.8% higher in patients with versus without diuretic use history.

Conclusions: GA growth rate may be associated with the fellow eye status, cholesterol-lowering medication use, and diuretic use. These possible associations do not infer causal relationships, and future prospective studies are required to investigate the relationships further.

Citing Articles

Age-related macular degeneration: natural history revisited in geographic atrophy.

Broadbent E, Kunzel S, Pfau M, Schmitz-Valckenberg S, Fleckenstein M Eye (Lond). 2024; 39(2):217-227.

PMID: 39472501 PMC: 11751078. DOI: 10.1038/s41433-024-03443-0.


Chorioretinal Atrophic Lesions Evolution in Patients with Quiescent Myopic Choroidal Neovascularization Followed for More Than 10 Years.

Ferreira A, Vilares-Morgado R, Lima-Fontes M, Falcao M, Falcao-Reis F, Carneiro A Clin Ophthalmol. 2024; 18:1381-1390.

PMID: 38770398 PMC: 11104444. DOI: 10.2147/OPTH.S461515.


Update on glial antibody-mediated optic neuritis.

Song H, Zhou H, Wei S Jpn J Ophthalmol. 2022; 66(5):405-412.

PMID: 35895155 DOI: 10.1007/s10384-022-00932-1.

References
1.
Rueden C, Schindelin J, Hiner M, DeZonia B, Walter A, Arena E . ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics. 2017; 18(1):529. PMC: 5708080. DOI: 10.1186/s12859-017-1934-z. View

2.
Xu X, Ritz B, Coleman A, Liew Z, Deapen D, Lee E . Hypertension, antihypertensive medications use and risk of age-related macular degeneration in California Teachers Cohort. J Hum Hypertens. 2019; 34(8):568-576. PMC: 7847248. DOI: 10.1038/s41371-019-0269-9. View

3.
Etminan M, Brophy J, Maberley D . Use of statins and angiotensin converting enzyme inhibitors (ACE-Is) and the risk of age-related macular degeneration: nested case-control study. Curr Drug Saf. 2008; 3(1):24-6. DOI: 10.2174/157488608783333952. View

4.
Smith W, Assink J, Klein R, Mitchell P, Klaver C, Klein B . Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001; 108(4):697-704. DOI: 10.1016/s0161-6420(00)00580-7. View

5.
Biarnes M, Arias L, Alonso J, Garcia M, Hijano M, Rodriguez A . Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study. Am J Ophthalmol. 2015; 160(2):345-353.e5. DOI: 10.1016/j.ajo.2015.05.009. View